Letters Section Editor: Robert M.
Golub, MD, Senior Editor.
To the Editor: Dr Bosch and colleagues1 considered the treatment of ANCA-associated vasculitis, discussing the relationship of its pathophysiology to current immunotherapy. The authors point out that although ANCA may be important in orchestrating neutrophil-mediated damage to the vascular endothelium, ANCA production is a T-cell driven process and novel forms of immunotherapy target this population of lymphocytes.
Wise MP, Frost P. Treatment of ANCA-Associated Vasculitis. JAMA. 2007;298(23):2739-2740. doi:10.1001/jama.298.23.2739-b